Here's what Bloomberg had to say about the Barron's article:
Coulter, IDEC, Sugen Among Analyst's Biotech Picks, Paper Says
Bloomberg News
May 16, 1998, 10:19 a.m. PT
Palo Alto, California, May 16 (Bloomberg) -- Coulter
Pharmaceutical Inc., IDEC Pharmaceuticals Corp. and Sugen Inc.
are among the biotechnology companies that could boost earnings
with promising cancer-fighting drugs, according to the head of
Lehman Brothers global health-care research team, C. Anthony
Butler, Barron's reported. Coulter and IDEC have both developed
drugs that could be combined together as an alternative to
chemotherapy treatments. Sugen, Ligand Pharmaceuticals Inc.,
EntreMed Inc. and Agouron Pharmaceuticals Inc. also have
developed drugs that show promise in treating certain cancers or
AIDS lesions, the paper reported.
This weekend's annual meeting in Los Angeles of the American
Society of Clinical Oncology is the largest ever, with 20,000 in
attendance, following heightened public interest in the potential
for cancer-fighting drugs.
(Barron's 5/18 22 www.barrons.com)
--Noam Neusner in the Princeton newsroom (609) 279-4091/shw |
